The U.S. Department of Veterans Affairs (VA) announced that its health care professionals will now be able to offer veterans with treatment-resistant depression therapy with the newly approved esketamine nasal spray drug, Spravato. Spravato will be made available to veterans based on clinical assessments conducted by VA medical professionals. Spravato is a Food and Drug Administration (FDA)-approved prescription treatment that is thought to work differently than currently approved therapies for major depressive disorder (MDD) and treatment- resistant depression (TRD). People who are currently struggling with MDD are considered to have TRD if they have not responded adequately . . .